Health Trials

Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer

ConditionsAnatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Endocrine Therapy-Induced AlopeciaPrognostic Stage I Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Prognostic Stage IB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexFemale
Age18+
SponsorOhio State University Comprehensive Cancer Center

About this trial

This early phase I trial studies the possible benefits and/or side effects of topical or oral minoxidil in treating endocrine therapy-induced hair loss (alopecia) in patients with stage I-IV breast cancer. Endocrine therapy-induced alopecia (EIA) is a distressing side effect that leads to reduced quality of life and early cessation of therapy in women undergoing treatment for breast cancer. Patients on endocrine therapy commonly report hair loss or thinning. Minoxidil is a drug that may promote hair growth and reduce hair loss. Oral minoxidil may increase hair density in women with EIA, and work the same as topical minoxidil in treating EIA in patients with breast cancer.

Eligibility criteria

Qualifiers

Women >= 18 years of age

Established diagnosis of breast cancer stages I-IV

On endocrine therapy including tamoxifen or aromatase inhibitors with or without concurrent use of ovarian function suppression

Self-reporting hair loss since starting endocrine therapy

Disqualifiers

Pregnant or nursing women

Current chemotherapy use or prior chemotherapy use within the last 2 years

History of scarring/cicatricial alopecia or alopecia areata

Prior use of oral or topical minoxidil

Trial design

Treatments tested in this trial

  • Minoxidil
  • Minoxidil
  • Quality-of-Life Assessment
  • Questionnaire Administration

Treatment groups

50 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Ohio State University Comprehensive Cancer Center

Lead sponsor

Source ClinicalTrials.gov